Clinical trials: sponsored by Hoffmann-La Roche
Non-Small Cell Lung Cancer
A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This open-label, multi-center study will evaluate the progression-free survival and safety of erlotinib in participants with locally advanced or metastatic non-small cell lung cancer with activating mutations in the tyrosine…
- Trial name
- ESSENCE (NCT01667562)
- Testing
- Erlotinib
- Where
- 4 sites in Serbia
- Volunteers
- 375 people
- Sponsor
- Hoffmann-La Roche
Non-Squamous Non-Small Cell Lung Cancer
A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy
This global, multicenter, open-label, randomized, controlled study evaluated the efficacy and safety of atezolizumab (an anti-programmed death-ligand 1 [anti-PD-L1] antibody)compared with docetaxel in participants with locally…
- Trial name
- OAK (NCT02008227)
- Testing
- Atezolizumab, Docetaxel
- Where
- 208 sites in United States, Argentina and 29 more
- Volunteers
- 1,225 people
- Sponsor
- Hoffmann-La Roche
Healthy Volunteer
A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers
A single-center, crossover study to evaluate the pharmacokinetics of dalcetrapib and atorvastatin from prototype fixed dose combination formulations in healthy volunteers.
- Trial name
- NCT01363999
- Testing
- atorvastatin, dalcetrapib
- Where
- New Zealand
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Healthy Volunteer
A Study of the Metabolic Profile of Dalcetrapib in Healthy Volunteers
This single center, open-label, non-randomized, one-treatment, one-period study will evaluate the metabolic profile and the safety of a single oral radiolabeled dose of dalcetrapib in male healthy volunteers.
- Trial name
- NCT01476267
- Testing
- dalcetrapib
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Solid Tumors
Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid Tumors
This is a Phase Ib, open-label, multicenter study designed to assess the safety, tolerability, and pharmacokinetics of coadministration of intravenous (IV) dosing of atezolizumab (an engineered anti-programmed death-ligand 1…
- Trial name
- NCT01988896
- Testing
- Atezolizumab, Cobimetinib
- Where
- 21 sites in United States, Australia and 4 more
- Volunteers
- 153 people
- Sponsor
- Hoffmann-La Roche
Solid Tumors
A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
This is an open-label, multicenter study designed to assess the safety, pharmacokinetics, pharmacodynamics and activity of Selicrelumab administered in combination with Atezolizumab (ATZ) in participants with metastatic or…
- Trial name
- NCT02304393
- Testing
- Atezolizumab, Selicrelumab
- Where
- 11 sites in United States, Canada and 4 more
- Volunteers
- 140 people
- Sponsor
- Hoffmann-La Roche
Bronchitis
A Safety Study of Balsamic Bactrim in Pediatric Participants With Acute Bronchitis
This pilot, multicentric and observational study will assess the safety of sulfamethoxazole + trimethoprim + guaifenesin (Balsamic Bactrim) in pediatric participants with acute bronchitis.
- Trial name
- NCT02879981
- Testing
- Guaifenesin, Sulfamethoxazole, Trimethoprim
- Where
- 3 sites in Peru
- Volunteers
- 51 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer
A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)
This is a Phase III, multicenter, open-label, three-arm, randomized study in participants with unresectable locally advanced or metastatic colorectal cancer (CRC) who have received at least two prior regimens of cytotoxic…
- Trial name
- NCT02788279
- Testing
- Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody, Cobimetinib, Regorafenib
- Where
- 73 sites in United States, Australia and 9 more
- Volunteers
- 363 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Non-Interventional Study in Patients With Moderate to Severe Rheumatoid Arthritis Treated With RoActemra/Actemra (Tocilizumab)
This non-interventional study will evaluate the use and efficacy of RoActemra/Actemra (tocilizumab) in patients with moderate to severe rheumatoid arthritis.
- Trial name
- NCT01663506
- Where
- 3 sites in Estonia
- Volunteers
- 23 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Non-Interventional Study of Tocilizumab Subcutaneous (SC) Monotherapy in Participants With Rheumatoid Arthritis (RA)
The aim of this non-interventional study in Hungarian participants is to gather real life data about the efficacy and safety of tocilizumab SC monotherapy in RA, to assess data about pattern of usage of tocilizumab monotherapy in…
- Trial name
- SIMPACT (NCT02402686)
- Testing
- Tocilizumab
- Where
- 18 sites in Hungary
- Volunteers
- 353 people
- Sponsor
- Hoffmann-La Roche
Healthy Volunteers
A Study to Investigate the Effect of Rifampicin on the PK of Multiple Doses of Balovaptin In Healthy Volunteers
This study was a single-center, non-randomized, open-label, one-sequence, two-period, within-subject study to investigate the effects of multiple doses of rifampicin on the PK and safety of multiple doses of balovaptan in healthy…
- Trial name
- NCT03586726
- Testing
- Balovaptan, Rifampicin
- Where
- Netherlands
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Juvenile Idiopathic Arthritis
A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)
This is a multi-center, open-label single-arm study to investigate the pharmacokinetics and safety of tocilizumab (RoActemra/Actemra) in participants less than 2 years old with active sJIA.
- Trial name
- NCT01455701
- Testing
- Tocilizumab
- Where
- 20 sites in United States, Argentina and 6 more
- Volunteers
- 11 people
- Sponsor
- Hoffmann-La Roche
Healthy Volunteers
A Study to Investigate the Effect of Itraconazole on the PK of Multiple Doses of Balovaptan in Healthy Volunteers
This study was a non-randomized, open-label, one-sequence, two-period within-subject study to investigate the effect of CYP3A inhibition on the PK of balovaptan in healthy male and female volunteers using itraconazole as a CYP3A…
- Trial name
- NCT03579719
- Testing
- Balovaptan, Itraconazole
- Where
- Netherlands
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Study to Compare the Efficacy of Tocilizumab With or Without Glucocorticoid Discontinuation in Rheumatoid Arthritis Participants
This Phase IIIb/IV, two-arm, randomized, double-blind, placebo-controlled, parallel-group, international, multicenter trial compares the change in disease activity (as assessed by Disease Activity Score in 28 joints [DAS28]…
- Trial name
- NCT02573012
- Testing
- Prednisone, Tocilizumab
- Where
- 39 sites in France, Germany and 4 more
- Volunteers
- 314 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer
This is a Phase 4, single-arm, open-label, multicenter study to assess the safety and efficacy of pertuzumab in combination with trastuzumab and docetaxel for the treatment of participants with human epidermal growth factor…
- Trial name
- NCT02445586
- Testing
- Docetaxel, Pertuzumab, Trastuzumab
- Where
- 9 sites in India
- Volunteers
- 52 people
- Sponsor
- Hoffmann-La Roche
Non-small Cell Lung Cancer
Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib
This randomized active-controlled multicenter Phase III open-label study will evaluate and compare between treatment groups the efficacy of alectinib versus chemotherapy in participants with ALK-positive advanced NSCLC who were…
- Trial name
- NCT02604342
- Testing
- Alectinib, Docetaxel, Pemetrexed
- Where
- 54 sites in Belgium, Bulgaria and 13 more
- Volunteers
- 119 people
- Sponsor
- Hoffmann-La Roche
Chronic Lymphocytic Leukemia
A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia
This multicenter, open-label, single-arm study will evaluate the safety and efficacy of obinutuzumab alone or in combination with chemotherapy in participants with previously untreated or relapsed/refractory chronic lymphocytic…
- Trial name
- NCT01905943
- Testing
- Bendamustine, Chlorambucil, Cyclophosphamide
- Where
- 174 sites in Argentina, Belgium and 29 more
- Volunteers
- 979 people
- Sponsor
- Hoffmann-La Roche
Sarcoma
A Study of Avastin (Bevacizumab) in Combination With Standard Chemotherapy in Children and Adolescents With Sarcoma.
This open-label two-arm study will assess the safety and efficacy of a combination of bevacizumab + standard chemotherapy with standard chemotherapy alone as active comparator in childhood and adolescent patients with metastatic…
- Trial name
- NCT00643565
- Testing
- Standard chemotherapy, bevacizumab [Avastin]
- Where
- 61 sites in Belgium, Brazil and 12 more
- Volunteers
- 154 people
- Sponsor
- Hoffmann-La Roche
Geographic Atrophy
A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study evaluating the efficacy and safety of lampalizumab administered by intravitreal injections in participants with geographic atrophy…
- Trial name
- SPECTRI (NCT02247531)
- Testing
- Lampalizumab
- Where
- 153 sites in United States, Argentina and 20 more
- Volunteers
- 975 people
- Sponsor
- Hoffmann-La Roche
Gastric Cancer, Gastroesophageal Junction Cancer
A Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab With Chemoradiotherapy in the Adjuvant Setting in Operated Participants With Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Gastric or Gastroesophageal Junction Cancer
This single-arm, open-label study will evaluate the safety and efficacy of the combination oxaliplatin, capecitabine, and trastuzumab with chemoradiotherapy in the adjuvant setting in participants with curatively resected HER2+…
- Trial name
- TOXAG (NCT01748773)
- Testing
- Oxaliplatin, Radiation, Capecitabine
- Where
- 9 sites in Turkey (Türkiye)
- Volunteers
- 34 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.